TRIHAN trial results published
Erasmus MC Rotterdam, department of Radiotherapy published the TRIHAN study results about the effects of the hyperthermia prototype combined with Radiotherapy in recurrent HNC patients.
The new Hypercollar3D deposits 80.5W/kg of power in the tumor volume (55% more than the Hypercollar). A complete response of the tumor after 12 weeks in 81,8% of patients was observed. Also, the 2 years Overall Survival (OS) and Local Control (LC) were similar compared to patients treated with chemoradiation. This finding is important since hyperthermia generally does not lead to systemic toxicity in contrast to chemotherapy. These findings inspire Sensius to create a commercial product, fit for routine clinical use.